DNA 0.00% 3.2¢ donaco international limited

Visitation declined at SV which I think is further indication of...

  1. 7,175 Posts.
    lightbulb Created with Sketch. 2021
    Visitation declined at SV which I think is further indication of the massive increase in casino capacity.

    The SV VIP business collapsed versus PCP and is a shadow of its former glory.

    On a normalised (for theoretical win rate) EBITDA basis SV declined versus the PCP.

    One of the worst acquisitions conducted by an ASX company from my memory.

    Aristo was the highlight for me. That business is firing up again. I would not be suprised if Aristo makes more than SV longer term. The Chinese are big punters.

    Plus, it actually has a solid market position where multiple competing casinos can't just pop up next door.

    The odds of China legalising gambling in the neighbouring province is also close to zero, unlike Thailand which seems inevitable, though still years before impact.

    Balance sheet is no longer an issue which is another big positive. Remains to be seen if they elect to pay dividends and/or conduct a buy back.

    Last edited by JoeGambler: 28/02/24
 
watchlist Created with Sketch. Add DNA (ASX) to my watchlist
(20min delay)
Last
3.2¢
Change
0.000(0.00%)
Mkt cap ! $39.53M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
2 254739 3.2¢
 

Sellers (Offers)

Price($) Vol. No.
3.3¢ 697415 2
View Market Depth
Last trade - 12.19pm 26/06/2024 (20 minute delay) ?
DNA (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.